Tailoring antiviral therapy in hepatitis C

被引：11

作者：

Davis, GL ^{[1
]}

机构：

[1] Baylor Univ, Med Ctr, Div Hepatol & Transplant Med, Baylor Reg Transplant Inst, Dallas, TX 75246 USA

来源：

HEPATOLOGY | 2006年 / 43卷 / 05期

关键词：

D O I：

10.1002/hep.21194

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：909 / 911

页数：3

共 18 条

[1]

Berg T, 2004, HEPATOLOGY, V40, p238A

[2] Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study [J].

Dalgard, O ;

Bjoro, K ;

Hellum, KB ;

Myrvang, B ;

Ritland, S ;

Skaug, K ;

Raknerud, N ;

Bell, H .

HEPATOLOGY, 2004, 40 (06) :1260-1265

[3] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].

Davis, GL ;

Wong, JB ;

McHutchison, JG ;

Manns, MP ;

Harvey, J ;

Albrecht, J .

HEPATOLOGY, 2003, 38 (03) :645-652

[4] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].

DAVIS, GL ;

BALART, LA ;

SCHIFF, ER ;

LINDSAY, K ;

BODENHEIMER, HC ;

PERRILLO, RP ;

CAREY, W ;

JACOBSON, IM ;

PAYNE, J ;

DIENSTAG, JL ;

VANTHIEL, DH ;

TAMBURRO, C ;

LEFKOWITCH, J ;

ALBRECHT, J ;

MESCHIEVITZ, C ;

ORTEGO, TJ ;

GIBAS, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506

[5] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[6]

Gross J, 2005, HEPATOLOGY, V42, p219A

[7] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

[8] Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy [J].

Jensen, DM ;

Morgan, TR ;

Marcellin, P ;

Pockros, PJ ;

Reddy, KR ;

Hadziyannis, SJ ;

Ferenci, P ;

Ackrill, AM ;

Willems, B .

HEPATOLOGY, 2006, 43 (05) :954-960

[9] Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 [J].

Mangia, A ;

Santoro, R ;

Minerva, N ;

Ricci, GL ;

Carretta, V ;

Persico, M ;

Vinelli, F ;

Scotto, G ;

Bacca, D ;

Annese, M ;

Romano, M ;

Zechini, F ;

Sogari, F ;

Spirito, F ;

Andriulli, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25) :2609-2617

[10] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].

Manns, MP ;

McHutchison, JG ;

Gordon, SC ;

Rustgi, VK ;

Shiffman, M ;

Reindollar, R ;

Goodman, ZD ;

Koury, K ;

Ling, MH ;

Albrecht, JK .

LANCET, 2001, 358 (9286) :958-965

← 1 2 →